Get the latest news, insights, and market updates on NRIX (Nurix Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertiseSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previ Nov 10, 2025 - $NRIX
What Nurix Therapeutics (NRIX)'s Phase 2 NX-5948 Trial Launch Means For Shareholders
Nurix Therapeutics recently announced the initiation of the pivotal Phase 2 DAYBreak trial of its BTK degrader candidate NX-5948 in relapsed or refractory chronic lymphocytic leukemia, alongside plans to present new clinical data at the upcoming American Society of Hematology Annual Meeting in December 2025. These advances underscore the company’s momentum in targeted protein degradation and suggest growing interest in their approach from both the scientific and investment communities. We'll... Nov 5, 2025 - $NRIX
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced that updated clinical data from the NX-5948-301 Phase 1a/1b clinical trial have been selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December Nov 3, 2025 - $NRIX
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences in November. Stifel 2025 Healthcare Conference, New York, NY Thursday, November 13, 2025, fr Oct 30, 2025 - $NRIX
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the closing of its previously announced underwritten registered offering of 24,485,799 shares of its common stock at a purchase price of $10.21 per share. The gross proceeds to Nurix from the offering were $250.0 Oct 27, 2025 - $NRIX
Nurix Therapeutics, Inc. (NRIX) Price Target Trimmed After Q3 Miss, Buy Rating Reaffirmed
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 14, H.C. Wainwright lowered its price target on Nurix Therapeutics (NASDAQ:NRIX) from $34.00 to $33.00, while reaffirming its Buy rating after the company’s Q3 2025 earnings. Nurix reported a net loss of $1.03 per share, wider […] Oct 26, 2025 - $NRIX
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the pricing of its underwritten registered offering of 24,485,799 shares of its common stock at a price of $10.21 per share. The gross proceeds to Nurix from the offering, before deducting underwriting discounts a Oct 22, 2025 - $NRIX
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a cl Oct 22, 2025 - $NRIX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.